Evaluating a Shared Decision Making Program for Crohn's Disease

Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease

Specific Aim: Study the impact of the Crohn's Disease Shared Decision Making Program on patients' treatment choice, persistence with chosen therapy, decision quality, cost of care, and outcomes

Hypothesis: The Crohn's Disease Shared Decision Making Program will help patients understand which treatments are right for them and will lead to a higher acceptance of appropriate therapy, improved persistence with chosen therapy, lower costs and improved clinical outcomes. To accomplish this aim, Investigators will perform a randomized controlled trial to:

1. Determine how the shared decision making program influences patients' choice of therapy
2. Evaluate how the shared decision making program affects persistence with chosen therapy
3. Determine how the shared decision making program affects decision quality
4. Determine how the shared decision making program influences cost of care and clinical outcomes

Expected Outcome and Impact: Investigators expect that this program will influence patients' choice of therapy, persistence with their preferred therapy, and lead to improved clinical outcomes. Investigators believe that this product can be successfully operationalized in the clinic to establish a new paradigm of how providers can communicate personalized treatment options to patients across a broad range of diseases.

Inclusion Criteria:

• Clinical diagnosis of Crohn's Disease based on standard clinical, radiographic, endoscopic, and histologic criteria
• Age 18 or older
• Fluent, English Speaking
• A candidate to receive immunomodulators or anti-TNF therapy based on their providers recommendation
• not currently taking immunomodulators (6-mercapropurine, azathioprine, methotrexate) or anti-TNF agents (infliximab, adalimumab, certolizumab pegol)

Exclusion Criteria:

• Participant in a pilot study/focus group for development of Crohn's Shared Decision Making Program
• Currently taking any medication that is contraindicated to take together with an immunomodulator or anti-TNF agent
• Known intolerance to either immunomodulators or anti-TNF agents
• Lack of accessibility to e-mail for follow-up surveys